Drug Profile
JY 09
Alternative Names: Exendin-4Fc fusion protein - Beijing Dongfang Biotech; JY-09Latest Information Update: 19 Feb 2024
Price :
$50
*
At a glance
- Originator Beijing Dongfang Biotech
- Class Antihyperglycaemics; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
- No development reported Diabetes mellitus
Most Recent Events
- 19 Feb 2024 Beijing Dongfang Biotech plans a phase III trial for Type 2 diabetes mellitus in China (SC, Injection) in March 2024 (NCT06257966)
- 12 Feb 2024 Beijing Dongfang Biotech plans a phase III trial for Type 2 diabetes mellitus in China (SC, Injection) in March 2024 (NCT06254014)
- 19 Oct 2023 Phase-I clinical trials in Type 2 diabetes mellitus (Combination therapy) in China (SC) (NCT06247748)